R&D The devil’s in the details: Navigating complexity & nuance i... Clinical trial expansion comes with complexity and increased risk, as each country has distinct regulatory requirements and contractual expectations.
Market Access Sustaining the mature product portfolio through strategic ou... Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.
Oncology The importance of globalisation for patient access At ESMO 2025 in Berlin, pharmaphorum spoke with Jo Feng, president of Hengrui Pharma.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.